Tempest Therapeutics, Inc. 8-K

What Happened

• Tempest Therapeutics, Inc. filed an 8-K (Item 5.02) reporting that Director Ms. Simantov notified the company of her resignation from the Board of Directors, effective May 23, 2026. The filing was submitted on May 29, 2026.

Key Details

• Resignation effective date: May 23, 2026.
• Filing: Current report on Form 8-K, Item 5.02 (departure of director).
• The company stated it has not been informed that the resignation resulted from any disagreement with the company regarding its operations, policies, or practices.
• The 8-K does not name a successor or indicate a replacement director in this filing.

Why It Matters

• Board changes affect corporate governance and oversight; investors should note the departure date and monitor future disclosures for any appointment of a replacement or changes to board composition.
• The company’s statement that the resignation was not due to a disagreement reduces immediate governance concerns, but investors may watch for further updates in subsequent SEC filings or proxy materials.